Friends of Cancer Research (Friends) is excited to announce the addition of City of Hope physician executive Edward S. Kim, M.D., M.B.A., FACP, FASCO, to its Board of Directors. Dr. Kim, recognized as one of the top cancer experts in the nation, is Physician-in-Chief and Senior Vice President, City of Hope Orange County, Construction Industries Alliance…
A new manuscript by Friends of Cancer Research (Friends) published today in JCO Clinical Cancer Informatics, details a framework to align electronic patient reported outcome (ePRO) data capture across ePRO tools to assess the value of ePROs for improving patient outcomes. This work can help expedite efforts to generate robust real-world data (RWD). PROs are…
Friends of Cancer Research (Friends) is pleased to support the most recent version of the Verifying Accurate Leading-edge IVCT Development Act (VALID Act) and urges Congress to include this as part of the 2023 omnibus appropriations bill. The VALID Act would resolve longstanding uncertainty associated with the regulation and use of diagnostic tests that play…
Friends of Cancer Research (Friends) is excited to announce new data from the Homologous Recombination Deficiency (HRD) Harmonization Project shared this weekend at The Association of Molecular Pathology Annual Meeting. The HRD Harmonization Project is a unique research partnership focused on understanding the variability in HRD assays and developing strategies to align methodology for measuring…
A new manuscript by Friends of Cancer Research (Friends) published in JCO Precision Oncology, finds strong associations between reductions in circulating tumor DNA (ctDNA) levels from on treatment liquid biopsies with improved overall survival and progression-free survival in non-small cell lung cancer (NSCLC). This manuscript highlights results that provide the initial basis of Friends’ ongoing…
Friends of Cancer Research (Friends) commends President Joe Biden on nominating Dr. Monica Bertagnolli as the Director of The National Cancer Institute (NCI). As the principal federal agency for cancer research and training, the NCI plays a critical role in advancing innovative science to benefit patients. We are deeply grateful to Dr. Ned Sharpless for…
Friends of Cancer Research (Friends) applauds the thoughtful work in constructing the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2022 – and particularly for including it in the Senate HELP user fee reauthorization bill (The FDA Safety and Landmark Advancements (FDASLA) Act). Diagnostic tests continue to be a growing component of cancer research and patient…
A new analysis conducted by Friends of Cancer Research (Friends) published today in Clinical Cancer Research, a journal of the American Association for Cancer Research, reveals that U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation (BTD) criteria select drugs that lead to better outcomes for patients with lung cancer. The study titled “Breakthrough Therapy…
Friends of Cancer Research (Friends) is encouraged by the notable progress being made within the House and Senate on the upcoming reauthorization of the FDA user fee programs. Representative Pallone and Representative McMorris-Rogers’s bill in the House as well as Senator Murray and Senators Burr’s newly released legislation in the Senate both support FDA programs to…
Friends of Cancer Research (Friends) would like to thank Dr. Ned Sharpless for his tireless public service and scientific leadership as Director of the National Cancer Institute (NCI) as well as his tenure as acting Commissioner of the U.S. Food and Drug Administration (FDA). “Dr. Sharpless deserves our country’s deep gratitude for his years of…
